← Evidence map

ArticleAmerican journal of clinical dermatology2024

Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'".

Yukari Okubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'". | OpenQuestion